Abstract Index

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000429232.99877.23
Abstract Index

    A101—Pattern of Mycobacterial Infections and their Associations with HIV among Laboratory Confirmed Cases of Pulmonary Tuberculosis in Nigeria

    Gumel Aliyu, Institute of Human Virology Nigeria

    A102—New Prevention Technologies, what does it mean for Nigeria?

    John Idoko, National Agency for Control of AIDS

    A103—Challenges of staying on the course for a HIV vaccine to end the epidemic in Africa

    Chidi Nweneka, African AIDS Vaccine Partnership

    A104—Improving laboratory capacity in Africa through step-wise accreditation program

    Alash’le Abimiku, Institute of Human Virology

    A105—Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda

    Andrew Kambugu, Makerere University College of Health Sciences

    A106—Neurocognitive Impairment among Treatment-Naïve HIV-Infected Individuals in Nigeria

    Walter Royal III, University of Maryland School of Medicine

    A107—Lymphoma incidence and HIV-related lymphoma subtypes seen at Tygerberg Academic Hospital, Western Cape, South Africa, 2002-2011

    Emmanuel A. Abayomi, Tygerberg Hospital, Stellenbosch University

    B101—Ten Draconian Changes in HIV Care for 2013

    John Bartlett, Johns Hopkins University School of Medicine

    B102—AIDSRelief: Lessons Learned

    Bruce Gilliam, Institute of Human Virology

    B103—The Zambian Medical Education Program

    Lottie Hachaambwa, Maryland Global Initiatives Corporation (MGIC) Zambia

    B104—Integrated Prevention of HIV: The Way Forward

    Myron Cohen, University of North Carolina

    B105—RV144: Progress in correlates, breakthrough viruses, and clinical development

    Jerome Kim, US Military HIV Research Program

    B106—New Nucleotides for the treatment of HIV infection

    James Rooney, Gilead Sciences

    B107—Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects

    Pablo Tebas, University of Pennsylvania

    B108—Therapeutic DNA vaccination in HIV-infected children and adolescents: 96 weeks data from the PEDVAC Trial

    Paolo Rossi, Children Hospital “Bambino Gesu”

    B109—Vacc-4x and Vacc-C5: Two peptide-based therapeutic HIV vaccine candidates

    Maja Sommerfelt, Bionor Immuno

    B110—Treatment for HCV in HIV Coinfected subjects: A new era of hope?

    Anuoluwapo Osinusi, CRMP, SAIC-Frederick Inc/NIAID, NIH

    B111—Genotypic resistance patterns in patients failing first line art regimen in Zambia

    Ignace Gashongore, Institute of Human Virology, Zambia

    B112—An Evaluation of Distance and its Impact on Long-term Follow up Outcomes in a Rural HIV Clinic in Northern Haiti

    Nephthalie Mesidor, Institute of Human Virology Haiti

    B113—Why Are They Dying? Describing Factors Associated With Mortality Among ART Patients in Rural Haiti

    Barbara Bastien, Institute of Human Virology Haiti

    B114—Proficiency Testing As a Quality Assessment Methodology in Acid Fast Bacilli Microscopy: The Experience of AIDSRelief

    Michael Mukiibi, Institute of Human Virology Nigeria

    B115—Effects of a Maternal Infant HIV Care Clinic for HIV-infected mothers and exposed infants on follow up postnatal HIV testing and care in Southeastern Nigeria: A retrospective review

    Anthea Nwandu, Institute of Human Virology Nigeria

    B116—Implementation of Cervical cancer screening services at 9 IHV/PEPFAR supported ART clinics in Uganda; Successes and challenges

    Emmanuel Mugisa, Institute of Human Virology Uganda

    C101—Viral Reservoirs in Elite Suppressors; a Possible Model for a Functional Cure?

    Joel Blankson, Johns Hopkins University

    C102—Cell-intrinsic HIV-1 immune defense in elite controllers

    Mathias Lichterfeld, Massachusetts General Hospital

    C103—Identification, purification and characterization of latently-infected cells using novel fluorescent HIV viruses

    Eric Verdin, University of California Francisco

    C104—Flow virometry: A nanotechnology for analysis of individual viral particles

    Leonid Margolis, National Institutes of Health

    C105—Glycosylation in HIV Transmission

    Jim Arthos, National Institutes of Health

    C106—Distinguishing Features of Transmitted/Founder HIV-1

    George Shaw, University of Pennsylvania

    C107—Preservation of Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with IL-21

    Mirko Paiardini, Emory

    C108—Impact of a live attenuated SIV vaccine on early events in transmission

    Ashley Haase, University of Minnesota

    D101—The cardinal rule of antibody - and CTL-eliciting vaccine design: specificity in a biological context

    Ellis Reinherz, Dana Farber Harvard

    D102—Molecular structures of trimeric HIV-1 and SIV envelope glycoproteins

    Sriram Subramaniam, National Institutes of Health

    D103—Structure, dynamics and antigenicity in HIV Env: A bridge from structure to phenotype and function

    Kelly Lee, University of Washington

    D104—Structural definition of new transitional epitopes exposed by CD4 binding to the HIV-1

    Marzena Pazgier, Institute of Human Virology

    D105—Reverse engineering HIV vaccines

    William Schief, IAVI and The Scripps Research Institute

    D106—Overcoming HIV Pathways for Escape using Rationally-Designed Anti-HIV Antibodies

    Pamela Bjorkman, California Institute of Technology

    D107—Effective CD4-binding-site antibodies: Atomic-level structures and ontogenies

    Peter Kwong, National Institute of Allergy and Infectious Diseases

    D108—Synthetic HIV-1 Glycopeptides Enable Characterization of Fine Epitopes of Broadly Neutralizing Antibody PG9

    Lai-Xi Wang, Institute of Human Virology

    D109—The role of Siglec in HIV infection

    Peter Sun, National Institutes of Health

    E101—Advances in Preventive HIV Vaccine Development

    Nelson Michael, U.S. Military HIV Research Program

    E102—Magnitude, Breadth and Duration of HIV-1 Vaccine-Elicited Neutralizing Antibody Responses

    David Montefiori, Duke University Medical Center

    E103—HIV-1 Vaccine Elicited IgA and IgG Antibody Specificities

    Georgia Tomaras, Duke University Medical Center

    E104—Identification of Three Distinct Epitope Regions in the V2 Portion of gp120

    Susan Zolla-Pazner, New York University

    E105—Exploring the role of conformational heterogeneity in the V1/V2 domain of HIV-1 gp120 on the immunological properties of Env immunogens

    Abraham Pinter, New Jersey Medical School

    E106—Diversity of Antibody Germline Gene and HIV-1 Infection: Implication for HIV-1 Vaccine

    Yongjun Guan, Institute of Human Virology

    E107—Complexity of human naïve B cell repertoires: The starting point for induction of neutralizing antibodies

    James Crowe, Vanderbilt

    E108—Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

    Barton Haynes, Duke University

    E109—Ending the HIV/AIDS Pandemic: Research and Implementation

    Anthony Fauci, National Institutes of Health

    E110—Antibodies to the gp120 envelope protein in protection of macaques from SIVmac251 acquisition

    Genoveffa Franchini, National Institutes of Health

    E111—Vaccine-microbicide combination studies in a rhesus macaque vaginal transmission model

    John Moore, Weill Medical College of Cornell University

    E112—DNA and combination vaccines for a durable and effective response

    George Pavlakis, National Cancer Institute

    E113—SIV control by vaccine-based Gag/Vif-specific CTL induction

    Tetsuro Matano, The University of Tokyo

    E114—Rational Design and Clinical Development of New Adjuvants

    Steven Reed, Infectious Disease Research

    G101—Studies at the oncogenic virus/host interface: Dynamic regulation of Epstein-Barr virus-mediated B cell immortalization

    Micah Luftig, Duke University

    G102—Activation of differentiation-dependent human papillomavirus life cycle through the ATM DNA damage pathway

    Lou Laimins, Northwestern University

    G103—The mechanisms by which HPV vaccines induce protection against HPV-associated cancers

    Doug Lowy, National Institutes of Health

    G104—Molecular Signatures in Human Liver Cancer

    Franco Buonaguro, Istituto Nazionale Tumori “Fond. G. Pascale”

    G105—Profibrogenic Chemokines and Viral Evolution Predict Rapid Progression of Hepatitis C to Cirrhosis

    Patrizia Farci, National Institutes of Health

    G106—Pathogenic roles of HTLV-1 bZIP factor gene

    Masao Matsuoka, Institute for Virus Research, Kyoto University

    G107—HIV-1 p17 variants induces Akt phosphorylation and B cell growth

    Arnaldo Caruso, University of Brescia

    © 2013 Lippincott Williams & Wilkins, Inc.